Presbyopia is the age-related decline in near vision that occurs as the eye gradually loses its ability to focus on close objects, resulting in blurry near vision. About 128 million people in the U.S. are impacted by presbyopia. Currently, there are only two FDA-approved eye drop solutions for the treatment of presbyopia - AbbVie Inc.'s Vuity and Orasis Pharmaceuticals' Qlosi.
The stock we are bringing to your attention today is that of LENZ Therapeutics Inc. (LENZ), a late clinical-stage biopharmaceutical company developing an eye drop solution for presbyopia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com